Extract
We read with great interest the recent publication by Kwak et al. [1] involving a meta-analysis of studies reporting treatment outcomes for Mycobacterium abscessus pulmonary disease (MAB-PD). The authors should be commended for identifying the association between azithromycin, amikacin and imipenem, and improved clinical outcome in MAB-PD.
Abstract
A combination of pharmacokinetics and pharmacodynamics is required to evaluate the efficacy of antimicrobial drugs in the treatment of Mycobacterium abscessus http://bit.ly/2OGwS3C
Footnotes
Conflict of interest: H.Y. Kim has nothing to disclose.
Conflict of interest: V. Sintchenko has nothing to disclose.
Conflict of interest: J-W. Alffenaar has nothing to disclose.
- Received July 30, 2019.
- Accepted August 1, 2019.
- Copyright ©ERS 2019
LIBRARY USERS
Log in through your institution
If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
Vol 54 Issue 5
Table of Contents
Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?
